Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapybenzinga_article·9 hours agoAKTX+5.04%
The Value Chain Shift: From Software Consolidation to Industrial RepositioningGlobal Report·14 hours agoVMEO0.00%SM+0.03%
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock NewsStockTitan·19 hours agoAKTX+5.04%
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformUnusual Whales·Aug 13 at 03:16 PMAKTX+5.04%
Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 millionPUBT·Aug 13 at 03:04 PMAKTX+5.04%WXXWY+4.08%
The Great Unbundling of 2026: From Legacy Aggregators to Frontier InfrastructureGlobal Report·Aug 4 at 04:17 AMNSRGF+1.59%IRDM-2.04%
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation | AKTX Stock NewsStockTitan·Aug 3 at 11:50 PMAKTX+5.04%WHWK+2.59%
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityGlobeNewswire·Jul 22 at 07:40 AMAKTX+5.04%WHWK+2.59%
